ES3056700T3 - Compositions and methods for treating myelin disorders - Google Patents

Compositions and methods for treating myelin disorders

Info

Publication number
ES3056700T3
ES3056700T3 ES18832119T ES18832119T ES3056700T3 ES 3056700 T3 ES3056700 T3 ES 3056700T3 ES 18832119 T ES18832119 T ES 18832119T ES 18832119 T ES18832119 T ES 18832119T ES 3056700 T3 ES3056700 T3 ES 3056700T3
Authority
ES
Spain
Prior art keywords
isp
amino acid
therapeutic agent
therapeutic
lpc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18832119T
Other languages
English (en)
Spanish (es)
Inventor
Jerry Silver
Fucheng Luo
Yan Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Application granted granted Critical
Publication of ES3056700T3 publication Critical patent/ES3056700T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18832119T 2017-07-11 2018-07-11 Compositions and methods for treating myelin disorders Active ES3056700T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531251P 2017-07-11 2017-07-11
PCT/US2018/041636 WO2019014342A1 (en) 2017-07-11 2018-07-11 COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES

Publications (1)

Publication Number Publication Date
ES3056700T3 true ES3056700T3 (en) 2026-02-24

Family

ID=65001812

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18832119T Active ES3056700T3 (en) 2017-07-11 2018-07-11 Compositions and methods for treating myelin disorders

Country Status (9)

Country Link
US (1) US20200230205A1 (https=)
EP (1) EP3651785B1 (https=)
JP (1) JP7538602B2 (https=)
KR (1) KR102772298B1 (https=)
CN (1) CN111093684A (https=)
AU (2) AU2018301399B2 (https=)
CA (1) CA3064463A1 (https=)
ES (1) ES3056700T3 (https=)
WO (1) WO2019014342A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240167030A1 (en) * 2021-04-02 2024-05-23 Case Western Reserve University Methods and compositions for accelerating oligodendrocyte maturation
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731058A (en) 1986-05-22 1988-03-15 Pharmacia Deltec, Inc. Drug delivery system
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5368562A (en) 1993-07-30 1994-11-29 Pharmacia Deltec, Inc. Systems and methods for operating ambulatory medical devices such as drug delivery devices
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US6841535B2 (en) 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
SI1931660T1 (sl) * 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
CA3233345A1 (en) * 2012-04-09 2013-10-17 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
US10258672B2 (en) * 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury

Also Published As

Publication number Publication date
AU2018301399B2 (en) 2024-08-29
JP2020527132A (ja) 2020-09-03
AU2024266863A1 (en) 2024-12-12
EP3651785C0 (en) 2025-11-12
AU2018301399A1 (en) 2019-12-19
WO2019014342A1 (en) 2019-01-17
CN111093684A (zh) 2020-05-01
JP7538602B2 (ja) 2024-08-22
CA3064463A1 (en) 2019-01-17
EP3651785A4 (en) 2021-07-07
KR20200039621A (ko) 2020-04-16
KR102772298B1 (ko) 2025-02-25
EP3651785B1 (en) 2025-11-12
EP3651785A1 (en) 2020-05-20
US20200230205A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7693290B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
US12129285B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
ES2750008T3 (es) Células madre mesenquimatosas modificadas genéticamente que expresan klotho
AU2024266863A1 (en) Compositions and methods for treating myelin disorders
Ng et al. Liver-specific adiponectin gene therapy suppresses microglial NLRP3-inflammasome activation for treating Alzheimer’s disease
CA3085576A1 (en) Peptides and other agents for treating pain and increasing pain sensitivity
US20210347821A1 (en) Inhibitors of pick1 and uses thereof
CN102946896A (zh) Sox9抑制剂
US10898550B2 (en) Compositions and methods of treating root avulsion injury
ES3023183T3 (en) Compositions and methods for treating neurological and other disorders
US20200093890A1 (en) Compositions and methods for treating alzheimer's disease
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
WO2007014156A2 (en) Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease
Li et al. Apoptotic extracellular vesicles derived from UC-MSCs promote spinal cord injury repair by inhibiting ferroptosis via OTUD1
US20240238385A1 (en) Isolated or artificial nucleotide sequences for use in neurodegenerative diseases
Bersani CELL PENETRATING PEPTIDE-CONJUGATED MORPHOLINO: A NOVEL COMPOUND TO RESCUE SMA IN A SYMPTOMATIC PHASE
WO2017198704A1 (en) Yif1b for the diagnosis, prevention and / or treatment of ciliopathies